Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus

scientific article published on 30 August 2016

Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/AJG.2016.348
P932PMC publication ID5209791
P698PubMed publication ID27575711

P50authorDavid C. WhitemanQ37837275
Lesley A AndersonQ41127233
Douglas A. CorleyQ110251065
P2093author name stringLiam J Murray
Nicholas J Shaheen
Joel H Rubenstein
Jennifer L Schneider
Hashem B El-Serag
Thomas L Vaughan
Michael B Cook
Aaron P Thrift
P2860cites workMeasuring inconsistency in meta-analysesQ27860655
Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequenceQ28182230
Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequenceQ28196944
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugsQ29617192
Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysisQ33555216
Incidence of adenocarcinoma and mortality in patients with Barrett's oesophagus diagnosed between 1976 and 1986: implications for endoscopic surveillanceQ34045322
Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagusQ34409880
Nonsteroidal anti-inflammatory drugs and the risk of Barrett's esophagusQ34429198
Prevalence of Barrett's esophagus in the general population: an endoscopic studyQ34475247
Central adiposity and risk of Barrett's esophagusQ34660127
Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagusQ35007536
Precision prevention of oesophageal adenocarcinomaQ35243217
Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, MinnesotaQ35565680
Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal refluxQ35596721
Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysisQ36212679
Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysisQ36370513
Prediction of Barrett's esophagus among men.Q37519245
The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trendsQ47322343
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomasQ47783937
Sex and Racial Disparity in Incidence of Esophageal Adenocarcinoma: Observations and ExplanationsQ48071285
The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagusQ50510790
Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluationQ51888144
Risk of mortality and cancer incidence in Barrett's esophagusQ52852873
Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trialQ53216462
Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosaQ59096214
Adenocarcinoma and Barrett's esophagus. An overrated risk?Q70587541
Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagusQ77794157
The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro studyQ77794185
P433issue11
P407language of work or nameEnglishQ1860
P921main subjectinflammationQ101991
Barrett's esophagusQ808892
P304page(s)1528-1535
P577publication date2016-08-30
P1433published inThe American Journal of GastroenterologyQ7713501
P1476titleNonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus
P478volume111

Reverse relations

cites work (P2860)
Q49227522Aspirin Use is Associated With Lower Risk of Barrett’s Esophagus in Women.
Q55375453Aspirin acts in esophageal cancer: a brief review.
Q48233200Aspirin prevents NF-κB activation and CDX2 expression stimulated by acid and bile salts in oesophageal squamous cells of patients with Barrett's oesophagus.
Q55395319Aspirin: the miracle drug?
Q54232649Barrett's Esophagus and Esophageal Adenocarcinoma: How Common Are They Really?
Q89285916Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma
Q93144923Diabetes in relation to Barrett's esophagus and adenocarcinomas of the esophagus: A pooled study from the International Barrett's and Esophageal Adenocarcinoma Consortium
Q47810183Impact of smoking, alcohol consumption, and NSAID use on risk for and phenotypes of eosinophilic esophagitis
Q58554442Precision care for Barrett's esophagus
Q39107022Redirecting the focus of cancer immunotherapy to premalignant conditions
Q36236462Risk Profiles for Barrett's Esophagus Differ between New and Prevalent, and Long- and Short-Segment Cases

Search more.